Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3157 Target Snapshot

B2 bradykinin receptor · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
2,327Compounds
221Assays
7Approved Drugs
2,507.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

B2 bradykinin receptor shows approved-linked disease relevance led by angioedema. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P30411. Start with angioedema, then reuse UniProt P30411 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with angioedema, then reuse UniProt P30411 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
angioedema

B2 bradykinin receptor shows approved-linked disease relevance led by angioedema. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with angioedema because it currently carries approved-linked support. Linked drugs include ICATIBANT ACETATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats B2 bradykinin receptor as ChEMBL target CHEMBL3157, mapped to UniProt P30411. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
B2 bradykinin receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL3157
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P30411
B2 bradykinin receptor
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether B2 bradykinin receptor is the right protein anchor across sources, using UniProt P30411 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why angioedema is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameB2 bradykinin receptor
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP30411
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelB2 bradykinin receptor
UniProt AccessionP30411
Component TypeProtein
Sequence Length391 aa

B2 bradykinin receptor

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as B2 bradykinin receptor, mapped to UniProt P30411. Sequence length is 391 aa.

Mapped IDP30411
Review nameB2 bradykinin receptor
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

B2 bradykinin receptor shows approved-linked disease relevance led by angioedema. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
angioedema
1 linked drug · 1 direct · 1 efficacy
Linked drugICATIBANT ACETATE
Approved-linked Approved
hereditary angioedema
1 linked drug · 1 direct · 1 efficacy
Linked drugICATIBANT ACETATE
Clinical signal Phase II
Central Nervous System Neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugLABRADIMIL
Clinical signal Phase II
COVID-19
1 linked drug · 1 direct · 1 efficacy
Linked drugICATIBANT ACETATE
Clinical signal Phase II
inflammation
1 linked drug · 1 direct · 1 efficacy
Linked drugICATIBANT ACETATE
Clinical signal Phase I
brain neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugLABRADIMIL
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with angioedema because it currently carries approved-linked support. Linked drugs include ICATIBANT ACETATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseangioedema
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

7
Approved
7
Phase II
Assay Mix

Activity Type Distribution

IC501,191.0
KI1,199.0
EC502.0
KD115.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL2028850 10.6 Ki 0.02512 Approved
CHEMBL1627325 10.47 EC50 0.03388 Preclinical
CHEMBL1956864 10.4 Ki 0.03981 Preclinical
CHEMBL406291 10.31 EC50 0.04898 Clinical
CHEMBL1956855 10.3 Ki 0.05012 Preclinical
CHEMBL1956856 10.3 Ki 0.05012 Preclinical
CHEMBL1956863 10.3 Ki 0.05012 Preclinical
CHEMBL1956876 10.3 Ki 0.05012 Preclinical
CHEMBL218427 10.3 Kd 0.05012 Clinical
CHEMBL218427 10.3 Ki 0.05012 Clinical
Distribution

pChEMBL Value Distribution

44
5.0
38
5.5
62
6.0
75
6.5
80
7.0
59
7.5
84
8.0
103
8.5
104
9.0
45
9.5
pChEMBL
Approved Drugs

Approved Drugs

ICATIBANT
CHEMBL2028850
Approved 2008
Properties Compare Identifier
Assay Landscape

Assay Landscape

221
Total Assays
541
Tested Compounds
3
Assay Types
Binding — 182 assays, 541 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 125 113 6.8
cell-based format 53 425 7.9
assay format 3 1 7.4
cell membrane format 1 2 4.9
Functional — 38 assays, 127 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 21 121 8.2
assay format 14 4 7.5
tissue-based format 3 2 9.3
ADME — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine